The U.S. Food and Drug Administration has issued several Emergency Use Authorizations for the use of COVID-19 therapeutics. Molnupiravir joins the list as the second oral antiviral to be administered in the outpatient setting for individuals with laboratory-confirmed COVID-19 who exhibit mild to moderate symptoms. We will review the indications, discuss available efficacy and safety data, and consider the clinical use of molnupiravir in light of the current dominant Omicron variant of concern. Product-specific requirements and counseling considerations will also be touched upon.
At the completion of this knowledge-based activity, pharmacists will be able to:
- Discuss eligibility requirements for the use of molnupiravir as outlined by the US Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA)
- Describe the mechanism of action of molnupiravir
- Discuss currently available efficacy and safety data on molnupiravir
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following education course is approved for 1.0 contact hour of CPE credit (0.1 CEU). The ACPE Universal Activity Number for this activity is 0202-0000-22-003-H01-P.
To obtain credit for completing Molnupiravir: An Oral Antiviral for the Treatment of COVID-19, participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: January 5, 2022
Expiration date: January 5, 2023 - No credit can be earned after this date
Molnupiravir: An Oral Antiviral for the Treatment of COVID-19 is an activity for pharmacists developed by the American Pharmacists Association. © 2022 American Pharmacists Association
Kieu Nguyen, PharmD and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
There is no fee associated with this activity for APhA members and non-members.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-22-003-H01-P||0.1 CEUs||January 05, 2022 - January 05, 2023|